European Journal of Surgical Oncology
Volume 35, Issue 10 , Pages 1048-1054, October 2009

Neoadjuvant bevacizumab, docetaxel and capecitabine combination therapy for HER2/neu-negative invasive breast cancer: Efficacy and safety in a phase II pilot study☆☆☆

  • R. Greil

      Affiliations

    • IIIrd Medical Department with Hematology and Medical Oncology, Private Medical University Hospital Salzburg, Muellner Hauptstrasse 48, Salzburg A-5020, Austria
    • Corresponding Author InformationCorresponding author. Tel.: +43 662 4482 2879; fax: +43 662 4482 2898.
    • ,
  • M. Moik

      Affiliations

    • IIIrd Medical Department with Hematology and Medical Oncology, Private Medical University Hospital Salzburg, Muellner Hauptstrasse 48, Salzburg A-5020, Austria
    • ,
  • R. Reitsamer

      Affiliations

    • Special Gynecology, Private Medical University Hospital, Salzburg, Austria
    • ,
  • S. Ressler

      Affiliations

    • IIIrd Medical Department with Hematology and Medical Oncology, Private Medical University Hospital Salzburg, Muellner Hauptstrasse 48, Salzburg A-5020, Austria
    • ,
  • M. Stoll

      Affiliations

    • IIIrd Medical Department with Hematology and Medical Oncology, Private Medical University Hospital Salzburg, Muellner Hauptstrasse 48, Salzburg A-5020, Austria
    • ,
  • K. Namberger

      Affiliations

    • IIIrd Medical Department with Hematology and Medical Oncology, Private Medical University Hospital Salzburg, Muellner Hauptstrasse 48, Salzburg A-5020, Austria
    • ,
  • C. Menzel

      Affiliations

    • Special Gynecology, Private Medical University Hospital, Salzburg, Austria
    • ,
  • B. Mlineritsch

      Affiliations

    • IIIrd Medical Department with Hematology and Medical Oncology, Private Medical University Hospital Salzburg, Muellner Hauptstrasse 48, Salzburg A-5020, Austria

Accepted 28 January 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

☆ Previously presented at the 30th San Antonio Breast Cancer Symposium, December 13–16, 2007 (abstract 4064).

☆☆ Sources of support: Roche Austria was sole sponsor of this trial, provided study medication (Taxotere in co-operation with Sanofi–Aventis) and was responsible for monitoring. Data management and statistical analysis were performed by Dr. Anton Klingler (Assign Data Management and Biostatistics GmbH; Feldstrasse 1, A-6020 Innsbruck, Austria).

PII: S0748-7983(09)00033-X

doi:10.1016/j.ejso.2009.01.014

European Journal of Surgical Oncology
Volume 35, Issue 10 , Pages 1048-1054, October 2009

Article Tools

* Image Usage & Resolution